Jortan Pharmaceuticals

Jortan Pharmaceuticals


Jortan Pharmaceuticals Inc. (JORTAN) was founded around aspartic protease inhibitors as potential diabetes therapeutics based on technology from the Oklahoma Medical Research Foundation (OMRF). BACE-2 has recently been identified as a key regulatory enzyme effecting pancreatic Beta-cell number and function (Esterhazy 2011). JORTAN has developed potent and selective BACE-2 (Memapsin 1) inhibitors as a novel approach to the treatment of diabetes. A drug that increases beta-cell number and function would be a very important advance in the treatment of both Type -1 (“Juvenile”) and Type-2 diabetes.

Learn more at

Request more information about Jortan

Support this research

  • Diabetes
  • Preclinical
  • Small Molecule